Results 161 to 170 of about 151,328 (264)

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

Systematic review of clinical trials and cohort studies evaluating HIV post‐exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background We conducted a systematic review of clinical trials and cohort studies on HIV post‐exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines. Methods We searched Medline and Embase (July 2017–June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and/
Stanley O. Onyegbule, Maryam Habib, Rija Khalid, Jessie Tu, Deborah Yoong, Jaris Swidrovich, Wale Ajiboye, Patrick O'Byrne, Ameeta E. Singh, Jean‐Guy Baril, Tatiana Sotindjo, Mark W. Hull, Darrell H. S. Tan   +12 more
wiley   +1 more source

Skin Resilience and Biological Adaptability: Current Clinical Evidence on Micronutrients and Bioactive Compounds. [PDF]

Biomedicines
Mihalache D, Gurau AM, Patrichi G, Gurau G, Satala CB.   +4 more
europepmc   +1 more source

A narrow bandgap Schottky heterojunction Fe2N/CeO2 microneedle triggering sonodynamic reactive oxygen species storm for drug‐resistance‐free skin fungal infection

BMEMat, EarlyView.
Inorganic sonosensitizers suffer from inefficient electron‐hole separation, rapid recombination, and wide bandgaps in anti‐fungal applications. We propose MN@Fe2N/CeO2 to directly eliminate fungi without drug resistance. Combining semiconductor CeO2's advantages with Fe2N's high work function and activity enables efficient Schottky heterojunctions ...
Li Wang, Jiayi Yang, Ning Tang, Youbin Zheng, Yichao Hou, Chutong Liu, Lihao Guo, Yingying Liao, Gandong Zhou, Weiwei Wu, Xin Du, Shuxiang Xu, Jie Yin, Miaomiao Yuan   +13 more
wiley   +1 more source

Transferosome Delivery Unlocks the Therapeutic Potential of Imiquimod for Experimental Cutaneous Leishmaniasis. [PDF]

Microorganisms
Flores GVA, Laurenti MD, Anaya BJ, Cavallone IN, Lalatsa A, de Lima Melchert SS, Tomokane TY, Sánchez SA, Serrano DR, Passero LFD.   +9 more
europepmc   +1 more source

From Surgical Innovation to Population Impact: Robot‐Assisted Radical Prostatectomy and the Evolution of Surgical Public Health in Brazil's Unified Health System

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Brazil's Unified Health System (Sistema Único de Saúde, SUS) represents one of the world's largest universal health systems and provides a unique real‐world platform for integrating prevention, diagnosis, treatment, and survivorship across the cancer continuum.
Leonardo Oliveira Reis
wiley   +1 more source

Glucocorticoids: an enemy or a friend for the dermatologist? recommendations for proper use and safe discontinuation. [PDF]

Endocrine
Sali E, Paschou IA, Dimopoulou SM, Tagka A, Chasapi V, Nicolaidou E, Stratigos AJ, Peppa M, Paschou SA.   +8 more
europepmc   +1 more source

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi, Eric Ricardo Yonatan, Tasia Esterita   +2 more
wiley   +1 more source

Sustained multisite response to anifrolumab in refractory Chilblain lupus erythematosus. [PDF]

JAAD Case Rep
John S, Scalzi LV, Foulke G, Helm M.
europepmc   +1 more source